MeSH D018307 - squamous cell neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals | Cemiplimab | Libtayo | 2019-06-28 | $1,093.7 M | Q4/23-Q3/24 |
Clinical Trials
Historical Success Rate
Phase 1
74%55/74
Phase 2
25%28/110
Phase 3
17%7/41
Approved: 0Overall Success rate: 3%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use